How Deprescribing in Psychiatry Offers a Path to Safer Care

What Deprescribing Really Means

Deprescribing is a clinical process, not a single decision. It includes reviewing the original reason for treatment, assessing whether that reason still applies, identifying adverse effects, discussing patient priorities, planning a gradual reduction when necessary, and monitoring what happens afterward.

The goal is not to reach zero medications. Some people need long-term or lifelong pharmacologic treatment, particularly for recurrent bipolar disorder, schizophrenia-spectrum illnesses, severe chronic depression, or other conditions with a high risk of relapse. In those situations, continuing medication may be the safest option.

The real goal is appropriate medication use: the fewest medications necessary, at the lowest effective doses, for clearly documented purposes. A treatment plan should be able to explain what every medication is doing. “It has been on the list forever” is not a therapeutic indication, although it is surprisingly common paperwork.

Why Psychiatry Needs a Deprescribing Mindset

Medication lists tend to grow more easily than they shrink

Psychiatric treatment often develops in layers. A patient starts an antidepressant, adds a sleep medication during a difficult month, receives a benzodiazepine for breakthrough anxiety, and later begins another drug to manage a side effect. Each decision may make sense at the time, but the complete regimen can eventually become more complicated than anyone intended.

This is sometimes called a prescribing cascade. One medication causes restlessness, sedation, insomnia, constipation, sexual dysfunction, weight gain, or cognitive slowing. Another medication is then added to treat the new symptom without first asking whether the original drug contributed to it.

Fragmented care can create psychiatric polypharmacy

A primary care physician, psychiatrist, sleep specialist, pain clinician, and emergency department may all prescribe medications affecting the central nervous system. If no one sees the whole picture, duplicate therapies and risky combinations can survive for years.

Polypharmacy does not automatically mean poor care. A person with several health conditions may legitimately need several medications. The concern is inappropriate polypharmacy: drugs without a current indication, overlapping treatments, excessive doses, harmful interactions, or therapies whose risks now outweigh their benefits.

Age and health changes can alter medication risk

The body does not process medication exactly the same way at 75 as it did at 35. Changes in kidney function, liver metabolism, body composition, balance, blood pressure, and cognitive reserve can make an old dose feel like a very different dose.

Older adults may be especially vulnerable to confusion, falls, daytime sedation, low blood pressure, anticholinergic effects, and drug interactions. Benzodiazepines and sedative-hypnotics deserve particular scrutiny because they can impair balance and cognition. That does not mean every older adult must immediately stop them. It means the risk-benefit discussion should not remain frozen in time.

When Should Psychiatric Deprescribing Be Considered?

A medication review may be appropriate when a drug no longer has a clear purpose, the original condition has resolved, the patient has been stable long enough to discuss alternatives, or side effects are interfering with daily life. Other signals include repeated falls, excessive sleepiness, emotional blunting, cognitive complaints, metabolic complications, movement symptoms, sexual dysfunction, or difficulty managing an increasingly complex schedule.

Deprescribing may also be considered when two drugs appear to serve the same function, when a short-term treatment quietly becomes permanent, or when a patient’s goals change. Someone who once prioritized immediate sedation during a crisis may later care more about mental sharpness, driving safety, work performance, or reducing medication burden.

High-risk combinations deserve prompt review. Examples include multiple sedating drugs or a benzodiazepine combined with an opioid, alcohol, or another central nervous system depressant. These combinations can increase sedation and respiratory risk.

Still, “consider deprescribing” does not mean “deprescribe at all costs.” A history of severe relapse, hospitalization, suicide attempts, dangerous mania, catatonia, or recurrent psychosis may strongly favor continued maintenance treatment. Safer care comes from individualized judgment, not blanket rules.

How Safe Psychiatric Deprescribing Works

1. Build one accurate medication list

The process begins with medication reconciliation. That means documenting prescriptions, over-the-counter sleep products, antihistamines, supplements, cannabis products, alcohol use, and medications obtained from other clinicians.

The list should include the dose, schedule, original indication, current benefit, duration of use, adverse effects, and responsible prescriber. Without this information, deprescribing becomes guesswork wearing a white coat.

2. Review benefits and harms one medication at a time

Clinicians and patients can examine what each medication was intended to accomplish and whether it is still accomplishing it. They should also consider withdrawal risk, relapse history, interactions, physical health, pregnancy plans, substance use, age, and the patient’s support system.

When a regimen is complicated, changing one medication at a time often makes the results easier to interpret. If three drugs are reduced simultaneously and insomnia appears, nobody knows which change caused it.

3. Use shared decision-making

Patients may feel relieved by the possibility of taking fewer medications, but they may also feel frightened. A drug may represent stability after years of illness. Suggesting a reduction can sound like, “You no longer deserve treatment,” even when the clinician intends the opposite.

Shared decision-making replaces pressure with partnership. The clinician explains the potential benefits and risks of continuing, reducing, or stopping treatment. The patient explains goals, fears, previous experiences, and practical constraints. Together, they agree on a plan with clear stopping points, monitoring arrangements, and permission to slow down.

4. Taper when withdrawal is possible

Many psychiatric medications should not be stopped abruptly after regular use. The nervous system adapts to medication exposure, and sudden discontinuation can produce symptoms that range from uncomfortable to dangerous.

A taper may take weeks or months, and some patients need even longer. The pace should reflect the medication, dose, duration of use, previous withdrawal reactions, medical risks, and the person’s response to each reduction. A calendar is useful, but symptoms get a vote.

5. Separate withdrawal symptoms from relapse

Withdrawal and recurrence of illness can look similar. Anxiety, insomnia, irritability, mood changes, physical discomfort, and agitation may occur in either situation. Timing provides clues: symptoms that begin soon after a dose reduction, include unfamiliar physical sensations, and improve after pausing or adjusting the taper may suggest withdrawal.

Relapse may more closely resemble the person’s previous illness pattern, although the distinction is not always tidy. Careful monitoring prevents a withdrawal reaction from being mislabeled as proof that the patient “needs the drug forever.” It also prevents a genuine return of illness from being dismissed as temporary discomfort.

6. Strengthen support before reducing medication

Deprescribing works best when something supportive replaces the function the medication was serving. That may include psychotherapy, cognitive behavioral therapy for insomnia, peer support, structured routines, exercise, substance-use treatment, family education, sleep hygiene, or closer clinical follow-up.

Removing a nightly sedative while leaving severe insomnia untreated is not a thoughtful plan. It is an alarm clock with paperwork.

7. Monitor, document, and adjust

A deprescribing plan should specify which symptoms to track, who to contact, when follow-up will occur, and what would justify pausing or reversing the taper. Depending on the drug, monitoring may include mood, sleep, anxiety, blood pressure, weight, glucose, movement symptoms, suicidal thinking, psychosis, or manic symptoms.

Restarting a previous dose is not necessarily failure. A taper is a clinical experiment conducted with consent. The result may be successful discontinuation, a lower maintenance dose, a slower reduction, or a well-supported decision to continue treatment.

Medication Classes That Require Special Care

Benzodiazepines

Benzodiazepines can provide rapid relief from anxiety, panic, agitation, muscle spasms, or insomnia. With regular use, however, physical dependence may develop. Abrupt discontinuation can cause intense anxiety, insomnia, tremor, perceptual disturbances, seizures, and other serious withdrawal reactions.

Current U.S. guidance emphasizes gradual, patient-specific tapering under clinical supervision. Some patients begin with a small percentage reduction and then adjust the pace according to symptoms. Faster is not automatically braver. Sometimes it is simply faster than the nervous system can comfortably handle.

Antidepressants

Stopping an antidepressant suddenly may produce dizziness, nausea, flu-like symptoms, sleep disturbance, irritability, anxiety, vivid dreams, imbalance, or electric-shock-like sensations. Risk varies among medications and patients.

A gradual reduction can lower the likelihood or severity of discontinuation symptoms. The decision to taper should also account for the number and severity of previous depressive episodes, duration of recovery, suicide risk, ongoing stressors, and access to psychotherapy or follow-up care.

Antipsychotics

Antipsychotic medications are essential for many people with schizophrenia, bipolar disorder, psychotic depression, and other serious conditions. They can also cause metabolic effects, sedation, movement disorders, elevated prolactin, and cardiovascular concerns.

Review is especially important when an antipsychotic was started for a temporary hospital-related problem, delirium, severe agitation, or behavior associated with dementia and then continued without reassessment. Reducing an antipsychotic in someone with recurrent psychosis requires particularly careful planning because relapse can have major consequences.

Mood stabilizers and other agents

Lithium, anticonvulsant mood stabilizers, stimulants, sleep medications, and medications used to control side effects each present different considerations. Some require laboratory monitoring, while others involve seizure risk, rebound symptoms, or changes in blood pressure and alertness.

There is no universal psychiatric taper. A plan copied from another patient, a social media post, or a well-meaning cousin with a spreadsheet may not fit the medication or the person taking it.

What a Safer Mental Health System Would Do Differently

A safer system would treat medication review as routine care rather than a rescue mission. Every psychiatric medication would have a documented indication, treatment goal, expected duration, monitoring plan, and scheduled review date.

Clinicians would discuss possible withdrawal and long-term risks when treatment begins, not only when a patient asks to stop. Pharmacists would be included in complex medication reviews. Electronic records would flag duplicate therapies and dangerous combinations without producing so many meaningless alerts that clinicians develop pop-up blindness.

Most importantly, health systems would make time for deprescribing. A ten-minute appointment is poorly suited to reviewing six psychiatric medications, explaining withdrawal, repairing trust, and building a monitoring plan. Safe simplification requires access, continuity, and follow-up.

The research base for deprescribing continues to develop, and not every intervention has been shown to improve every clinical outcome. Even so, major patient-safety organizations consistently recognize supervised medication reduction as an important strategy for addressing potentially inappropriate treatment and medication-related harm.

Experiences From the Deprescribing Process

The following composite experiences illustrate common lessons from psychiatric care. They are not descriptions of specific patients, and they should not be used as personal medical instructions.

The sleep medication that stayed for twelve years

Consider an older adult who began taking a benzodiazepine after the death of a spouse. At the time, sleep was nearly impossible, anxiety was intense, and short-term treatment helped. The prescription was renewed month after month, long after the original crisis had changed.

Years later, the patient reported daytime fatigue, forgetfulness, and two falls. No single symptom proved that the medication was responsible, but the overall picture justified a review. The first conversation did not begin with, “We are stopping this.” It began with, “What does this medication still help, and what worries you about changing it?”

The patient feared another sleepless period more than the medication’s potential risks. The care team therefore introduced behavioral treatment for insomnia, reviewed evening habits, involved a pharmacist, and agreed on a slow reduction with frequent check-ins. Several dose changes were delayed because of family stress. Eventually, the patient reached a much lower dose and felt more alert during the day.

The lesson was not that everyone should stop benzodiazepines. It was that a successful plan addressed the reason the patient continued taking one.

The antidepressant taper mistaken for relapse

In another common experience, a patient who had been well for several years decided to stop an antidepressant. The dose was reduced quickly. Within days, dizziness, nausea, vivid dreams, anxiety, and unusual electrical sensations appeared.

The patient assumed depression had returned and felt defeated. A clinician reviewed the timing and symptom pattern and considered antidepressant discontinuation rather than immediate relapse. The taper was paused, the plan was revised, and later reductions were smaller and more widely spaced.

This experience highlights why language matters. Calling every difficult reaction a relapse may convince patients that discontinuation is impossible. Calling every symptom withdrawal may overlook a genuine recurrence of illness. Good care remains curious long enough to tell the difference.

The medication added for the side effect of another medication

A third composite case involves a patient taking an antipsychotic, an antidepressant, a medication for restlessness, a sedative for sleep, and another drug for constipation. Each prescription had a story, but no one had recently reviewed the complete plot.

Instead of removing several medications at once, the treatment team clarified which condition was active, which symptoms were side effects, and which drug contributed the least benefit. One medication was reduced first while mood, sleep, movement symptoms, and functioning were tracked.

The patient initially worried that fewer prescriptions meant the clinician doubted the seriousness of the illness. The clinician explained that deprescribing was intended to improve treatment quality, not minimize suffering. That conversation changed the tone from suspicion to collaboration.

Over time, the regimen became simpler. Not every medication was stopped, and that was not a disappointment. The patient retained the treatments that provided clear protection while shedding some of the burden surrounding them.

The experience patients remember most

Across these situations, the most important experience is often not the final medication count. It is whether the patient felt heard. Forced or poorly explained reductions can damage trust, trigger withdrawal, and push people away from care. Collaborative reductions can strengthen confidence because patients learn that the plan can respond to their bodies and priorities.

Deprescribing is safest when it moves at the speed of informed consent. It requires humility from clinicians, patience from everyone involved, and an acceptance that the neatest medication list is not always the healthiest one.

Conclusion: Better Prescribing Includes Knowing When to Reconsider

Psychiatric medications should neither be glorified as permanent solutions nor treated as villains waiting in amber bottles. They are tools. Like all tools, they should be used for a defined purpose, checked for wear, and reconsidered when the job changes.

Deprescribing in psychiatry offers a path to safer care because it brings attention back to the individual. It can reduce unnecessary medication burden, reveal avoidable side effects, lower interaction risks, and create treatment plans that better reflect a patient’s current life.

The safest approach is gradual, collaborative, and reversible. It respects the benefits medications may have provided while acknowledging that yesterday’s prescription is not entitled to automatic renewal forever. Sometimes excellent psychiatric care means starting a medication. Sometimes it means continuing one. And sometimes it means carefully helping a patient need less.